{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:21:22Z","timestamp":1793985682638,"version":"4.8.0"},"posted":{"date-parts":[[2024,1,11]]},"group-title":"HIV\/AIDS","reference-count":36,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the only bnAb HIV prevention efficacy studies to date, the Antibody Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01, administered intravenously (IV), demonstrated 75% prevention efficacy against highly neutralization-sensitive viruses but was ineffective against less sensitive viruses. Greater efficacy is required before passively administered bnAbs become a viable option for HIV prevention; furthermore subcutaneous (SC) or intramuscular (IM) administration may be preferred. VRC07-523LS is a next-generation bnAb targeting the CD4-binding site and was engineered for increased neutralization breadth and half-life.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants were recruited between 02 February 2018 and 09 October 2018. 124 healthy participants without HIV were randomized to receive five VRC07-523LS administrations via IV (T1: 2.5 mg\/kg, T2: 5 mg\/kg, T3: 20 mg\/kg), SC (T4: 2.5 mg\/kg, T5: 5 mg\/kg) or IM (T6: 2.5 mg\/kg or P6: placebo) routes at four-month intervals. Safety data were collected for 144 weeks following the first administration. VRC07-523LS serum concentrations were measured by ELISA after the first dose through Day 112 in all participants and by binding antibody multiplex assay (BAMA) thereafter in 60 participants (10 per treatment group) through Day 784. Compartmental population pharmacokinetic (PK) analyses were conducted to evaluate the VRC07-523LS serum pharmacokinetics. Neutralization activity was measured in a TZM-bl assay and anti-drug antibodies (ADA) were assayed using a tiered bridging assay testing strategy.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Injections were well-tolerated, with mild pain or tenderness reported commonly in the SC and IM groups, and mild to moderate erythema or induration reported commonly in the SC groups. Infusions were generally well-tolerated, with infusion reactions reported in 3 of 20 participants in the 20 mg\/kg IV group. Peak geometric mean (GM) concentrations (95% confidence intervals) following the first administration were 29.0 \u03bcg\/mL (25.2, 33.4), 58.5 \u03bcg\/mL (49.4, 69.3), and 257.2 \u03bcg\/mL (127.5, 518.9) in T1-T3 with IV dosing; 10.8 \u03bcg\/mL (8.8, 13.3) and 22.8 \u03bcg\/mL (20.1, 25.9) in T4-T5 with SC dosing; and 16.4 \u03bcg\/mL (14.7, 18.2) in T6 with IM dosing. Trough GM concentrations immediately prior to the second administration were 3.4 \u03bcg\/mL (2.5, 4.6), 6.5 \u03bcg\/mL (5.6, 7.5), and 27.2 \u03bcg\/mL (23.9, 31.0) with IV dosing; 0.97 \u03bcg\/mL (0.65, 1.4) and 3.1 \u03bcg\/mL (2.2, 4.3) with SC dosing, and 2.6 \u03bcg\/mL (2.05, 3.31) with IM dosing. Peak VRC07-523LS serum concentrations increased linearly with the administered dose. At a given dose, peak and trough concentrations, as well as serum neutralization titres, were highest in the IV groups, reflecting the lower bioavailability following SC and IM administration. A single participant was found to have low titre ADA at a lone timepoint. VRC07-523LS has an estimated mean half-life of 42 days (95% CI: 40.5, 43.5), approximately twice as long as VRC01.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>VRC07-523LS was safe and well-tolerated across a range of doses and routes and is a promising long-acting bnAb for inclusion in HIV-1 prevention regimens.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.01.10.23299799","type":"posted-content","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T08:50:20Z","timestamp":1704963020000},"source":"Crossref","is-referenced-by-count":3,"title":["A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127\/HPTN 087)"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-9370","authenticated-orcid":false,"given":"Stephen R.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly T.","family":"Karuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ollivier","family":"Hyrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8317-7685","authenticated-orcid":false,"given":"Timothy","family":"Skalland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7460-733X","authenticated-orcid":false,"given":"Kenneth H.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena E.","family":"Sobieszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"del Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3651-2721","authenticated-orcid":false,"given":"Guiseppe","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carissa","family":"Karg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonglin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8640-6623","authenticated-orcid":false,"given":"Carmen A.","family":"Paez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A. G.","family":"Baumblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5476-7632","authenticated-orcid":false,"given":"Laura L.","family":"Polakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wairimu","family":"Chege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Janto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunda","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dumond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-3476","authenticated-orcid":false,"given":"Margaret E.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian B.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Flach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Piwowar-Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2009-3270","authenticated-orcid":false,"given":"Kelly","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8076-1931","authenticated-orcid":false,"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-6319","authenticated-orcid":false,"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Mascola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"HVTN 127\/HPTN 087 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2024011301050624000_2024.01.10.23299799v1.1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-110918-034551"},{"key":"2024011301050624000_2024.01.10.23299799v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4"},{"key":"2024011301050624000_2024.01.10.23299799v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"2024011301050624000_2024.01.10.23299799v1.4","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 Fact sheet [Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"2024011301050624000_2024.01.10.23299799v1.5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-110118-045506"},{"key":"2024011301050624000_2024.01.10.23299799v1.6","doi-asserted-by":"crossref","unstructured":"Walsh SR , Seaman MS . Broadly Neutralizing Antibodies for HIV-1 Prevention. Front Immunol. 2021;12:712122.","DOI":"10.3389\/fimmu.2021.712122"},{"key":"2024011301050624000_2024.01.10.23299799v1.7","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02213-14"},{"key":"2024011301050624000_2024.01.10.23299799v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/nature13612"},{"key":"2024011301050624000_2024.01.10.23299799v1.9","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1601"},{"issue":"10","key":"2024011301050624000_2024.01.10.23299799v1.10","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","year":"2019","journal-title":"Lancet HIV"},{"key":"2024011301050624000_2024.01.10.23299799v1.11","unstructured":"WHO. WHO preferred product characteristics for monoclonal antibodies for HIV prevention [Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240045729."},{"issue":"5","key":"2024011301050624000_2024.01.10.23299799v1.12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/QAI.0000000000002369","article-title":"Social Impacts Among Participants in HIV Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials","volume":"84","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024011301050624000_2024.01.10.23299799v1.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113425"},{"key":"2024011301050624000_2024.01.10.23299799v1.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1301456110"},{"key":"2024011301050624000_2024.01.10.23299799v1.15","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01708-08"},{"key":"2024011301050624000_2024.01.10.23299799v1.16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007730"},{"key":"2024011301050624000_2024.01.10.23299799v1.17","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-170-3_26"},{"key":"2024011301050624000_2024.01.10.23299799v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2013.11.022"},{"key":"2024011301050624000_2024.01.10.23299799v1.19","unstructured":"Mkhize NN , Mapengo RE , Bekker V , Modise T , Kgagudi P , Lambson BE , et al., editors. Neutralization profiles of HIV-1 subtype C breakthrough viruses from the Southern African VRC01 AMP trial (HVTN 703\/HPTN 081). HIVR4P; 2023; Virtual."},{"key":"2024011301050624000_2024.01.10.23299799v1.20","doi-asserted-by":"crossref","first-page":"112764","DOI":"10.1016\/j.jim.2020.112764","article-title":"Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies","volume":"479","year":"2020","journal-title":"J Immunol Methods"},{"key":"2024011301050624000_2024.01.10.23299799v1.21","doi-asserted-by":"publisher","DOI":"10.1198\/sbr.2009.0008"},{"issue":"4","key":"2024011301050624000_2024.01.10.23299799v1.22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/psp4.12500","article-title":"Efficient Pharmacokinetic Modeling Workflow With the MonolixSuite: A Case Study of Remifentanil","volume":"9","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"2024011301050624000_2024.01.10.23299799v1.23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/QAI.0000000000002892","article-title":"Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials","volume":"89","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024011301050624000_2024.01.10.23299799v1.24","doi-asserted-by":"crossref","unstructured":"Huang Y , Naidoo L , Zhang L , Carpp LN , Rudnicki E , Randhawa A , et al. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. EBioMedicine. 2021;64:103203.","DOI":"10.1016\/j.ebiom.2020.103203"},{"key":"2024011301050624000_2024.01.10.23299799v1.25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002493"},{"key":"2024011301050624000_2024.01.10.23299799v1.26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002435"},{"issue":"8","key":"2024011301050624000_2024.01.10.23299799v1.27","doi-asserted-by":"crossref","first-page":"e0219142","DOI":"10.1371\/journal.pone.0219142","article-title":"Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study","volume":"14","year":"2019","journal-title":"PLoS One"},{"issue":"10","key":"2024011301050624000_2024.01.10.23299799v1.28","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","article-title":"Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial","volume":"27","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"2024011301050624000_2024.01.10.23299799v1.29","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","year":"2022","journal-title":"Nat Med"},{"key":"2024011301050624000_2024.01.10.23299799v1.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0186-4"},{"issue":"10","key":"2024011301050624000_2024.01.10.23299799v1.31","doi-asserted-by":"crossref","first-page":"e653","DOI":"10.1016\/S2352-3018(23)00140-6","article-title":"Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10\u20131074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial","volume":"10","year":"2023","journal-title":"Lancet HIV"},{"key":"2024011301050624000_2024.01.10.23299799v1.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005520"},{"key":"2024011301050624000_2024.01.10.23299799v1.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-042247"},{"issue":"4","key":"2024011301050624000_2024.01.10.23299799v1.34","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(23)00003-6","article-title":"Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial","volume":"10","year":"2023","journal-title":"Lancet HIV"},{"key":"2024011301050624000_2024.01.10.23299799v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01953-6"},{"key":"2024011301050624000_2024.01.10.23299799v1.36","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.50"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.01.10.23299799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:48:05Z","timestamp":1768506485000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.01.10.23299799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":36,"URL":"https:\/\/doi.org\/10.1101\/2024.01.10.23299799","relation":{},"subject":[],"published":{"date-parts":[[2024,1,11]]},"subtype":"preprint"}}